Nitazoxanide
- Generic Name
- Nitazoxanide
- Brand Names
- Alinia, Busulfex
- Drug Type
- Small Molecule
- Chemical Formula
- C12H9N3O5S
- CAS Number
- 55981-09-4
- Unique Ingredient Identifier
- SOA12P041N
- Background
Nitazoxanide belongs to the class of drugs known as thiazolides. Nitazoxanide (NTZ) is a broad-spectrum anti-infective drug that markedly modulates the survival, growth, and proliferation of a range of extracellular and intracellular protozoa, helminths, anaerobic and microaerophilic bacteria, in addition to viruses. This drug is effective in the treatment of gastrointestinal infections including Cryptosporidium parvum or Giardia lamblia in healthy subjects. It is generally well tolerated. Nitazoxanide is a first-line, standard treatment for illness caused by C. parvum or G. lamblia infection in healthy (not immunosuppressed) adults and children and may also be considered in the treatment of illnesses caused by other protozoa or helminths . Recently, this drug has been studied as a broad-spectrum antiviral agent due to its ability to inhibit the replication of several RNA and DNA viruses .
- Indication
用于治疗隐孢子虫、贾第鞭毛虫、阿米巴原虫引起的原虫性腹泻。
- Associated Conditions
- Diarrhea caused by Cryptosporidium parvum, Diarrhea caused by Giardia lamblia
A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19
- Conditions
- SARS-CoV InfectionCovid19
- Interventions
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2022-05-05
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 7
- Registration Number
- NCT04605588
- Locations
- 🇺🇸
Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
COVID-19 Prophylaxis South Africa (COVER HCW)
- Conditions
- SARS-CoV InfectionCovid19
- Interventions
- Drug: Sofosbuvir/Daclatasvir
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2022-06-07
- Lead Sponsor
- University of Witwatersrand, South Africa
- Target Recruit Count
- 1950
- Registration Number
- NCT04561063
- Locations
- 🇿🇦
Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, Gauteng, South Africa
🇿🇦Sunnyside Office Park, Johannesburg, Gauteng, South Africa
Nitazoxanide Therapy for Patients With COVID-19 Pneumonia
- Conditions
- Covid19Pneumonia, ViralCorona Virus Infection
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2021-07-22
- Lead Sponsor
- Universidade Federal do Rio de Janeiro
- Target Recruit Count
- 500
- Registration Number
- NCT04561219
- Locations
- 🇧🇷
Universidade Federal do Rio de Janeiro, Rio De Janeiro, Brazil
Effects of Early Use of Nitazoxanide in Patients With COVID-19
- First Posted Date
- 2020-09-17
- Last Posted Date
- 2020-11-03
- Lead Sponsor
- Universidade Federal do Rio de Janeiro
- Target Recruit Count
- 392
- Registration Number
- NCT04552483
- Locations
- 🇧🇷
Universidade Federal do Rio de Janeiro, Rio De Janeiro, Brazil
Catalysing the Containment of COVID-19
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2022-08-16
- Lead Sponsor
- University of Cape Town
- Target Recruit Count
- 322
- Registration Number
- NCT04523090
- Locations
- 🇿🇦
The Aurum Institute, Tembisa, Gauteng, South Africa
🇿🇦University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa
🇿🇦Perinatal HIV Research Unit, Klerksdorp, North West, South Africa
Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19
- First Posted Date
- 2020-08-05
- Last Posted Date
- 2020-11-12
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 240
- Registration Number
- NCT04498936
- Locations
- 🇪🇬
Assiut University Hospital, Assiut, Egypt
🇪🇬15th May Hospital, Helwan, Cairo, Egypt
Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection
- Conditions
- EnterovirusRhinovirus
- Interventions
- First Posted Date
- 2020-07-28
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Romark Laboratories L.C.
- Target Recruit Count
- 214
- Registration Number
- NCT04489381
- Locations
- 🇺🇸
HealthStar Research LLC, Hot Springs, Arkansas, United States
🇺🇸Invesclinic US LLC, Fort Lauderdale, Florida, United States
🇺🇸RH Medical Urgent Care, Bronx, New York, United States
Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Romark Laboratories L.C.
- Target Recruit Count
- 935
- Registration Number
- NCT04486313
- Locations
- 🇺🇸
Invesclinic US LLC, Fort Lauderdale, Florida, United States
🇺🇸RH Medical Urgent Care, Bronx, New York, United States
Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoV-2 Virus Infection (COVID-19)
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Laboratorios Roemmers S.A.I.C.F.
- Target Recruit Count
- 135
- Registration Number
- NCT04463264
- Locations
- 🇦🇷
Hospital Universitario Austral, Presidente Derqui, Buenos Aires, Argentina, Argentina
The Nitazoxanide Plus Atazanavir for COVID-19 Study
- Conditions
- Covid-19
- Interventions
- Other: Standard of Care
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Obafemi Awolowo University
- Target Recruit Count
- 57
- Registration Number
- NCT04459286
- Locations
- 🇳🇬
Olabisi Onabanjo University Teaching Hospital, Sagamu, Ogun State, Nigeria
🇳🇬Infectious Disease Hospital, Olodo, Ibadan, Oyo State, Nigeria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.